Robert Iannone
CIK 1737329 · EVP, Global Head of R&D & CMO · last filed 2026-07-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$21.87M
Companies
6
Total Filings
42
Lifetime Open-Market Net
-$2.80M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PLRX | Director | — | $1.07 | — | $0 | 1 | 2026-07-13 |
| JAZZ | EVP, Global Head of R&D & CMO | 85,107 | $256.92 | $21.87M | -$2.80M | 23 | 2026-07-02 |
| AUTL | Director | — | $1.45 | — | $0 | 1 | 2026-07-01 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Director | — | $10.15 | — | $0 | 5 | 2024-06-13 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | — | $1.88 | — | $0 | 6 | 2023-05-04 |
| IMMUNOMEDICS INC (IMMU) Delisted | CHIEF MEDICAL OFFICER | — | — | — | $0 | 2 | 2019-03-18 |
Recent Filings · Page 2 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-07 | JAZZ | Notice (144) | −4,017 | -$571.5K | EDGAR |
| 2025-03-07 | JAZZ | Notice (144) | −5,466 | -$758.3K | EDGAR |
| 2025-03-07 | JAZZ | Mixed | −12,319 | -$1.71M | EDGAR |
| 2025-03-03 | JAZZ | Grant (A) | +26,577 | $0 | EDGAR |
| 2025-01-22 | JAZZ | Mixed | +5,325 | -$267.4K | EDGAR |
| 2024-06-13 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-07 | JAZZ | Tax (F) | −4,294 | -$504.7K | EDGAR |
| 2024-03-05 | JAZZ | Grant (A) | +16,928 | $0 | EDGAR |
| 2024-01-19 | JAZZ | Mixed | +4,240 | -$206.1K | EDGAR |
| 2023-06-15 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.